文献速递皮肤肿瘤

羟基脲和芦可替尼预治疗的真性红细胞增多症患者发生侵袭性皮肤鳞状细胞癌

Aggressive cutaneous squamous cell carcinoma in a hydroxyurea- and ruxolitinib-pretreated patient with polycythaemia vera.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2022-01-01

一例85岁真性红细胞增多症男性,长期接受羟基脲和芦可替尼治疗,因头皮进行性增大的肿瘤就诊。最大头皮病灶组织病理示部分促纤维增生性皮肤鳞状细胞癌伴神经周围侵犯,初始影像示颈部淋巴结、骨和肺转移。头皮病灶经博来霉素为主电化学治疗成功,但转移灶在四周期西妥昔单抗后进展,经保险批准后 compassionate use 帕博利珠单抗单药三周期后转移灶进一步进展,患者最终死于全身性呼吸功能不全。

要点

  • 长期羟基脲和芦可替尼治疗与侵袭性非黑色素瘤皮肤癌发生相关。
  • 头皮皮肤鳞状细胞癌可伴神经周围侵犯和促纤维增生,并出现淋巴结、骨和肺转移。
  • 博来霉素为主电化学治疗可成功处理头皮病灶,但转移灶对西妥昔单抗和帕博利珠单抗均进展。

核心结论

  • 本例提示长期羟基脲和芦可替尼治疗可致皮肤不良反应,常发生高度侵袭性非黑色素瘤皮肤癌,且通常对系统性治疗包括免疫检查点抑制剂无应答。

研究设计与样本

  • 病例报告:一例85岁男性真性红细胞增多症患者,有羟基脲和芦可替尼治疗史。

主要发现

  • 最大头皮病灶组织病理示部分促纤维增生性皮肤鳞状细胞癌伴神经周围侵犯。
  • 初始影像示颈部淋巴结、骨和肺转移。
  • 头皮病灶经博来霉素为主电化学治疗成功。
  • 初始系统性治疗使用四周期西妥昔单抗,转移灶进展。
  • 经保险批准后 compassionate use 帕博利珠单抗单药,三周期后转移灶进一步进展,患者最终死于全身性呼吸功能不全。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hydroxyurea and ruxolitinib are frequently used to treat myeloproliferative disorders, including polycythaemia vera, and chronic treatment is associated with many cutaneous adverse effects such as the development of aggressive non-melanoma skin cancer (NMSC). We report an 85-year-old man with a history of hydroxyurea- and ruxolitinib-treated polycythaemia vera who was referred for the management of progressively growing tumours on his scalp. Histopathology of the largest scalp lesion revealed a partly desmoplastic cutaneous squamous carcinoma with perineural invasion. Initial imaging revealed metastatic disease in cervical lymph nodes, bones and lungs. The scalp lesions were successfully treated with bleomycin-based electrochemotherapy. Under initial systemic therapy using four cycles of cetuximab, metastatic disease progressed. Following the approval by the health insurance, compassionate use of pembrolizumab monotherapy was initiated. After three cycles of pembrolizumab, however, metastatic disease further progressed and the patient finally died from global respiratory insufficiency. The present case exemplifies the cutaneous adverse effects of long-term hydroxyurea and ruxolitinib therapy, frequently resulting in highly aggressive NMSCs that are usually not responsive to systemic treatments even such as immune checkpoint inhibitors.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Gambichler T, Stockfleth E, Susok L, et al. Aggressive cutaneous squamous cell carcinoma in a hydroxyurea- and ruxolitinib-pretreated patient with polycythaemia vera. J Eur Acad Dermatol Venereol. 2022. PMID: 34855240. doi:10.1111/jdv.17406

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。